Welcome to our dedicated page for Neurobo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on Neurobo Pharmaceuticals stock.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), now operating under the name MetaVia Inc., generates a steady stream of news as a clinical-stage biotechnology company focused on cardiometabolic diseases. Company announcements highlight progress with its two primary investigational drugs: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
News items commonly cover clinical trial milestones, such as completion of enrollment, last patient last visit, and top-line data readouts from the Phase 1 program of DA-1726 and the Phase 2a program of DA-1241. Releases also describe the design of these studies, including single and multiple ascending dose components for DA-1726 and the two-part, randomized, double-blind, placebo-controlled structure of the DA-1241 MASH trial.
Investors following NRBO-related news can also expect corporate updates, including the strategic realignment around cardiometabolic assets, the announced corporate name change to MetaVia Inc. with an expected Nasdaq ticker change to MTVA, and financing transactions that support the advancement of DA-1726 and DA-1241. Financial results releases provide context on research and development spending, general and administrative expenses, and cash runway in relation to planned clinical milestones.
Additional news coverage includes participation in investor and scientific conferences, joint research agreements related to DA-1726 and DA-1241, and collaborations described in SEC filings. For users tracking NRBO, this news feed offers a consolidated view of historical and transitional developments as the company continues its cardiometabolic drug development under the MetaVia identity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has submitted an Investigational New Drug (IND) application to the FDA for DA-1241, a GPR119 agonist targeting nonalcoholic steatohepatitis (NASH). This milestone follows the acquisition of DA-1241 and aims to address the unmet needs in NASH treatment. Preclinical results suggest DA-1241 may reduce liver fat and improve glucose metabolism. The Phase 2a trial will include 87-98 subjects, focusing on changes in ALT levels as the primary endpoint. Upcoming key milestones include patient enrollment in Q3 2023 and data expected in H2 2024. NeuroBo also plans to progress DA-1726 through the IND process this year.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has announced its strategic focus on cardiometabolic diseases following the acquisition of promising assets targeting nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes. The company completed a public offering of $17.3 million and received a $15 million private investment from Dong-A, becoming its largest shareholder. For 2022, R&D expenses decreased to $2.8 million, while net loss narrowed to $14.0 million, or $5.43 per share. Cash and equivalents rose to $33.4 million, expected to support operations into 2024, including upcoming clinical trials for DA-1241 and DA-1726.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company (Nasdaq: NRBO), has appointed Joseph Hooker as Interim CEO and President following the retirement of Gil Price. Hooker, who brings approximately 40 years of industry experience, will lead the company during its search for a permanent CEO. The Board expressed confidence in Hooker's ability to advance NeuroBo's newly acquired assets, DA-1241 and DA-1726, into clinical development, particularly targeting nonalcoholic steatohepatitis (NASH) and obesity. In November 2022, NeuroBo secured $32.3 million in financing to bolster its financial position and support ongoing operations.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has closed a public offering generating $17.3 million and a concurrent private placement raising $15 million. The public offering included 3,147,003 Class A Units and 2,602,997 Class B Units, priced at $3.00 each. NeuroBo also secured an exclusive license from Dong-A ST Co., Ltd. for DA-1241 and DA-1726, aimed at treating NASH, obesity, and type 2 diabetes. The license includes an upfront payment of $22 million worth of Series A Convertible Preferred Stock. Stockholder meetings are anticipated by December 22, 2022.